Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis

Subba Chintalacharuvu, Glenn F. Evans, Chuan Shih, Henry U. Bryant, George Sandusky, Steven H. Zuckerman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To determine the effects of a glycinamide ribonucleotide formyltransfei-ase (GARFT) inhibitor on macrophage inflammatory processes and in vivo in rat adjuvant arthritis. Methods: GARFT inhibitors, LY309886 (6S-2′,5′-thienyl-5,10-dideazatetrahydrofolic acid) and LY329201 (R)-N-[[5-[2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3- d]pyrimidin-6-yl)ethyl]-2-thienyl]carbonyl]-L-glutamatic acid disodium salt, were investigated in vitro and ex vivo on primary murine peritoneal macrophages and in the RAW macrophage cell line for both purine depletion and inhibition of LPS induced monokine secretion. In vivo efficacy following GARFT inhibition was evaluated in modified rat adjuvant arthritis. Results: LY309886 inhibited purine biosynthesis in the RAW cell line with an EC50 of 90 nM, an effect readily reversible with exogenous hypoxanthine. LY309886 and LY329201 also inhibited LPS induced TNF alpha and MIP1 alpha in these cells and in primary macrophages. A similar effect could be demonstrated ex vivo with mice dosed for two days with 3 mg/kg of LY329201. LY329201 as well as methotrexate demonstrated a dose dependent reduction in both paw and spleen weight and improved joint histology following 2 weeks of dosing in a rat adjuvant arthritis study. Conclusion: These results suggest that GARFT inhibitors should be tested in the treatment of rheumatoid arthritis by considering their mechanism of action, here successfully tested on activated macrophages.

Original languageEnglish (US)
Pages (from-to)438-446
Number of pages9
JournalClinical and Experimental Rheumatology
Volume23
Issue number4
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

LY329201
Hydroxymethyl and Formyl Transferases
6R-2',5'-thienyl-5,10-dideazatetrahydrofolic acid
Experimental Arthritis
Macrophages
Cytokines
Monokines
Cell Line
Hypoxanthine
Peritoneal Macrophages
Methotrexate
Rheumatoid Arthritis
Histology
Spleen
Tumor Necrosis Factor-alpha
Joints
In Vitro Techniques
glycinamide ribonucleotide
Weights and Measures

Keywords

  • Anti-folates
  • Inflammation
  • Macrophage inflammatory protein 1
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis. / Chintalacharuvu, Subba; Evans, Glenn F.; Shih, Chuan; Bryant, Henry U.; Sandusky, George; Zuckerman, Steven H.

In: Clinical and Experimental Rheumatology, Vol. 23, No. 4, 07.2005, p. 438-446.

Research output: Contribution to journalArticle

@article{f8cea60d070547d1b8f23b42a8bb889e,
title = "Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis",
abstract = "Objective: To determine the effects of a glycinamide ribonucleotide formyltransfei-ase (GARFT) inhibitor on macrophage inflammatory processes and in vivo in rat adjuvant arthritis. Methods: GARFT inhibitors, LY309886 (6S-2′,5′-thienyl-5,10-dideazatetrahydrofolic acid) and LY329201 (R)-N-[[5-[2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3- d]pyrimidin-6-yl)ethyl]-2-thienyl]carbonyl]-L-glutamatic acid disodium salt, were investigated in vitro and ex vivo on primary murine peritoneal macrophages and in the RAW macrophage cell line for both purine depletion and inhibition of LPS induced monokine secretion. In vivo efficacy following GARFT inhibition was evaluated in modified rat adjuvant arthritis. Results: LY309886 inhibited purine biosynthesis in the RAW cell line with an EC50 of 90 nM, an effect readily reversible with exogenous hypoxanthine. LY309886 and LY329201 also inhibited LPS induced TNF alpha and MIP1 alpha in these cells and in primary macrophages. A similar effect could be demonstrated ex vivo with mice dosed for two days with 3 mg/kg of LY329201. LY329201 as well as methotrexate demonstrated a dose dependent reduction in both paw and spleen weight and improved joint histology following 2 weeks of dosing in a rat adjuvant arthritis study. Conclusion: These results suggest that GARFT inhibitors should be tested in the treatment of rheumatoid arthritis by considering their mechanism of action, here successfully tested on activated macrophages.",
keywords = "Anti-folates, Inflammation, Macrophage inflammatory protein 1, Tumor necrosis factor",
author = "Subba Chintalacharuvu and Evans, {Glenn F.} and Chuan Shih and Bryant, {Henry U.} and George Sandusky and Zuckerman, {Steven H.}",
year = "2005",
month = "7",
language = "English (US)",
volume = "23",
pages = "438--446",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "4",

}

TY - JOUR

T1 - Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis

AU - Chintalacharuvu, Subba

AU - Evans, Glenn F.

AU - Shih, Chuan

AU - Bryant, Henry U.

AU - Sandusky, George

AU - Zuckerman, Steven H.

PY - 2005/7

Y1 - 2005/7

N2 - Objective: To determine the effects of a glycinamide ribonucleotide formyltransfei-ase (GARFT) inhibitor on macrophage inflammatory processes and in vivo in rat adjuvant arthritis. Methods: GARFT inhibitors, LY309886 (6S-2′,5′-thienyl-5,10-dideazatetrahydrofolic acid) and LY329201 (R)-N-[[5-[2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3- d]pyrimidin-6-yl)ethyl]-2-thienyl]carbonyl]-L-glutamatic acid disodium salt, were investigated in vitro and ex vivo on primary murine peritoneal macrophages and in the RAW macrophage cell line for both purine depletion and inhibition of LPS induced monokine secretion. In vivo efficacy following GARFT inhibition was evaluated in modified rat adjuvant arthritis. Results: LY309886 inhibited purine biosynthesis in the RAW cell line with an EC50 of 90 nM, an effect readily reversible with exogenous hypoxanthine. LY309886 and LY329201 also inhibited LPS induced TNF alpha and MIP1 alpha in these cells and in primary macrophages. A similar effect could be demonstrated ex vivo with mice dosed for two days with 3 mg/kg of LY329201. LY329201 as well as methotrexate demonstrated a dose dependent reduction in both paw and spleen weight and improved joint histology following 2 weeks of dosing in a rat adjuvant arthritis study. Conclusion: These results suggest that GARFT inhibitors should be tested in the treatment of rheumatoid arthritis by considering their mechanism of action, here successfully tested on activated macrophages.

AB - Objective: To determine the effects of a glycinamide ribonucleotide formyltransfei-ase (GARFT) inhibitor on macrophage inflammatory processes and in vivo in rat adjuvant arthritis. Methods: GARFT inhibitors, LY309886 (6S-2′,5′-thienyl-5,10-dideazatetrahydrofolic acid) and LY329201 (R)-N-[[5-[2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3- d]pyrimidin-6-yl)ethyl]-2-thienyl]carbonyl]-L-glutamatic acid disodium salt, were investigated in vitro and ex vivo on primary murine peritoneal macrophages and in the RAW macrophage cell line for both purine depletion and inhibition of LPS induced monokine secretion. In vivo efficacy following GARFT inhibition was evaluated in modified rat adjuvant arthritis. Results: LY309886 inhibited purine biosynthesis in the RAW cell line with an EC50 of 90 nM, an effect readily reversible with exogenous hypoxanthine. LY309886 and LY329201 also inhibited LPS induced TNF alpha and MIP1 alpha in these cells and in primary macrophages. A similar effect could be demonstrated ex vivo with mice dosed for two days with 3 mg/kg of LY329201. LY329201 as well as methotrexate demonstrated a dose dependent reduction in both paw and spleen weight and improved joint histology following 2 weeks of dosing in a rat adjuvant arthritis study. Conclusion: These results suggest that GARFT inhibitors should be tested in the treatment of rheumatoid arthritis by considering their mechanism of action, here successfully tested on activated macrophages.

KW - Anti-folates

KW - Inflammation

KW - Macrophage inflammatory protein 1

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=26844549171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844549171&partnerID=8YFLogxK

M3 - Article

C2 - 16095110

AN - SCOPUS:26844549171

VL - 23

SP - 438

EP - 446

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 4

ER -